Van Bogaert Patrick, Azizieh Regis, Désir Julie, Aeby Alec, De Meirleir Linda, Laes Jean-François, Christiaens Florence, Abramowicz Marc J
Department of Pediatric Neurology, Université Libre de Bruxelles, Hôpital Erasme, Brussels, Belgium.
Ann Neurol. 2007 Jun;61(6):579-86. doi: 10.1002/ana.21121.
We investigated a large consanguineous Moroccan family with progressive myoclonic epilepsy (PME) consistent with autosomal recessive inheritance, to describe the phenotype and identify the causal gene.
We recorded the clinical course of the disease and the response to drug therapy, whereas carefully excluding known causes of progressive myoclonic epilepsy. We then linked the disease by homozygosity mapping using microsatellite markers and single nucleotide polymorphism microarrays (11K GeneChip), and studied candidate genes in the critical linkage region.
Epilepsy started between 16 and 24 months of age after normal initial development. Seizures were multifocal myoclonus aggravated by movements, and generalized tonic-clonic seizures were experienced by two patients. Electroencephalogram showed slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges, and photosensitivity. Brain magnetic resonance images were normal. All patients were demented. Two had refractory epilepsy and a severe course. Seizures were controlled in the third patient, whose disease course was less severe. Linkage analyses identified a new locus on 7q11.2, with a maximum multipoint logarithm of odds of 4.0 at D7S663. In the critical linkage region, we found a C to T mutation in exon 2 of the potassium channel tetramerization domain containing 7 gene (KCTD7). The mutation affected a highly conserved segment of the predicted protein, changing an arginine codon into a stop codon (R99X).
Neurodegeneration in progressive myoclonic epilepsy presented by our patients paralleled the refractoriness of epilepsy. The disease was transmitted as an autosomal recessive trait linked to a novel locus at 7q11.2, where we identified a mutation in KCTD7.
我们研究了一个患有与常染色体隐性遗传相符的进行性肌阵挛癫痫(PME)的摩洛哥近亲大家族,以描述其表型并确定致病基因。
我们记录了疾病的临床病程以及对药物治疗的反应,同时仔细排除进行性肌阵挛癫痫的已知病因。然后,我们使用微卫星标记和单核苷酸多态性微阵列(11K基因芯片)通过纯合性定位来关联该疾病,并研究关键连锁区域中的候选基因。
癫痫在正常初始发育后的16至24个月龄之间开始。发作表现为运动加重的多灶性肌阵挛,两名患者经历过全身性强直阵挛发作。脑电图显示慢节律紊乱、多灶性且偶尔全身性癫痫样放电以及光敏性。脑磁共振成像正常。所有患者均患有痴呆症。两名患者患有难治性癫痫且病程严重。第三名患者的癫痫发作得到控制,其病程较轻。连锁分析在7q11.2上确定了一个新位点,在D7S663处最大多点对数优势为4.0。在关键连锁区域,我们在含钾通道四聚化结构域7基因(KCTD7)的外显子2中发现了一个从C到T的突变。该突变影响了预测蛋白质的一个高度保守片段,将一个精氨酸密码子变为一个终止密码子(R99X)。
我们患者所呈现的进行性肌阵挛癫痫中的神经退行性变与癫痫的难治性平行。该疾病作为常染色体隐性性状遗传,与7q11.2处的一个新位点相关联,我们在该位点鉴定出了KCTD7中的一个突变。